



July 20, 2016

Corium to Present Clinical Data from a Phase 1 Pharmacokinetic Study of Once-Weekly Corplex™ Donepezil Transdermal System

Results to be presented at Alzheimer's Association International Conference® 2016

MENLO PARK, Calif., July 20, 2016 (GLOBE NEWSWIRE) --

Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Parminder "Bobby" Singh, Ph.D., Corium's Chief Technology Officer and Vice President, Research and Development, will present clinical data from a Phase 1 pharmacokinetic study of Corium's once-weekly Corplex Donepezil product candidate at the Alzheimer's Association International Conference 2016 (AAIC) in Toronto, Ontario.

The objective of the Phase 1 study was to evaluate the pharmacokinetics, safety and tolerability of once-weekly Corplex Donepezil compared to Eisai's Aricept® once-daily oral tablet taken for seven consecutive days.

Poster Presentation Details:

Pharmacokinetic Data from Phase 1 Study of Once-Weekly Corplex Donepezil Transdermal System as Therapeutic Alternative to Daily Oral Aricept

- | Wednesday, July 27, 2016, 1:00-2:00 p.m. EDT
- | Location: Metro Toronto Convention Centre, Hall D/E
- | Session: P4-14 Developing Topics: Poster Presentations
- | Poster #12229

About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Endo Pharmaceuticals and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumgroup.com.

Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.

Aricept® is a registered trademark of Eisai R&D Management Co., Ltd.

Investor and Media Contacts:

BCC Partners

Karen L. Bergman

kbergman@bccpartners.com

(650) 575-1509

Susan Pietropaolo

spietropaolo@bccpartners.com

(845) 638-6290

[</p><p>
<p>
	</p>
<p>
	Source: <org idsrc=" xmltag.org"="" value="NASDAQ-NMS:CORI">](https://resource.globenewswire.com/Resource/Download/a0238dad-f0e9-4f12-839c-ae370d6c08d7?/)

[Corium International, Inc.](#)

-

-

[News Provided by Acquire Media](#)